doi:10.3969/j.issn.1004-583X.2026.05.013

Abstract

CLC Number:

R692.3

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.05.013

https://www.lchc.cn/EN/Y2026/V41/I5/468

References 67

[1]	Xu JJ, Cai J, Hu B. Renal histopathological manifestations of IgA vasculitis nephritis in children and adults[J]. Int Immunopharmacol, 2023, 116: 109760.doi:10.1016/J.Intimp.2023.109760.
[2]	Zhang Y, Xu G. IgA vasculitis with nephritis: An overview of the pathogenesis and clinical characteristics[J]. Clin Exp Rheumatol, 2025, 43(4): 728-741.doi:10.55563/clinexprheumatol/mjhyff.
[3]	Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)[J]. Kidney Int, 2025, 108(4S): S1-S71.doi:10.1016/j.kint.2025.04.004. pmid: 40975564
[4]	中国IgA肾病协作组(IIgANN-China)科学委员会, 中华预防医学会肾脏病预防与控制专业委员会. 中国成人IgA肾病及IgA血管炎肾炎临床实践指南(2025)[J]. 中华内科杂志, 2025, 64(10): 918-944.doi:10.3760/cma.j.cn112138-20250707-00396.
[5]	Xi L, Sun Y, Chen Y, et al. Clinicopathological features and prognosis of IgA vasculitis nephritis with nephrotic-range proteinuria in children[J]. Pediatr Nephrol, 2024, 39(11): 3241-3250.doi:10.1007/s00467-024-06441-2. pmid: 38980322
[6]	Luo X, Tan J, Wan D, et al. Predictability of the Oxford classification of IgA nephropathy in Henoch-Schonlein purpura nephritis[J]. Int Urol Nephrol, 2022, 54(1): 99-109.doi:10.1007/S11255-021-02861-3.
[7]	Hastings MC, Rizk DV, Kiryluk K, et al. IgA vasculitis with nephritis: Update of pathogenesis with clinical implications[J]. Pediatr Nephrol, 2022, 37(4): 719-733.doi:10.1007/S00467-021-04950-Y.
[8]	Huang X, Wu J, Wu XM, et al. Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Schönlein purpura)-related nephritis: A cohort in the adult Chinese population[J]. BMC nephrology, 2018, 19(1): 334.doi:10.1186/s12882-018-1117-9. pmid: 30466400
[9]	刘宇立, 姚瑶, 徐锦雯. 过敏性紫癜性肾炎患儿肾功能不全的影响因素分析[J]. 中华肾病研究电子杂志, 2024, 13(2): 68-73.doi:10.3877/cma.j.issn.2095-3216.2024.02.002.
[10]	Liu Z, Wei YD, Hou Y, et al. Differences in pathological characteristics and laboratory indicators in adult and pediatric patients with Henoch-Schönlein purpura nephritis[J]. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(5): 659-666.doi:10.1007/s11596-016-1642-3.
[11]	Wang Y, Wang H, Ma X, et al. Characteristics of renal pathology and coagulation function in IgA nephropathy and IgA vasculitis associated nephritis[J]. BMC Nephrol, 2024, 25(1): 35. doi: 10.1186/s12882-024-03465-6. pmid: 38273279
[12]	Lv Y, Fu R, Peng XJ, et al. Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children[J]. BMC Pediatr, 2023, 23(1): 423.doi:10.1186/s12887-023-04243-3. pmid: 37620917
[13]	Wang M, Wang R, He X, et al. Using MEST-C scores and the international study of kidney disease in children classification to predict outcomes of Henoch-Schönlein purpura nephritis in children[J]. Front Pediatr, 2021, 9: 658845.doi:10.3389/fped.2021.658845.
[14]	Peruzzi L, Coppo R. IgA vasculitis nephritis in children and adults: One or different entities?[J]. Pediatr Nephrol, 2021, 36(9): 2615-2625.doi:10.1007/s00467-020-04818-7. pmid: 33219450
[15]	Berthelot L, Jamin A, Viglietti D, et al. Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort[J]. Nephrol Dial Transplant, 2018, 33(9): 1579-1590.doi:10.1093/ndt/gfx300.
[16]	Pillebout E, Jamin A, Ayari H, et al. Biomarkers of IgA vasculitis nephritis in children[J]. PLoS One, 2017, 12(11): e0188718.doi:10.1371/journal.pone.0188718.
[17]	Zhang X, Xie X, Shi S, et al. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis[J]. Nephrol Dial Transplant, 2020, 35(12): 2117-2123.doi:10.1093/ndt/gfz151.
[18]	Podraza Z, Poplicha K, Ufniarski T, et al. Laboratory findings and clinical features in IgA vasculitis: Identifying predictors of kidney involvement and disease relapse in pediatric patients[J]. J Clin Med, 2025, 14(9): 3055.doi:10.3390/jcm14093055.
[19]	侯方兴, 胡蓉蓉, 张硕, 等. 异常糖基化IgA1在紫癜性肾炎发病机制和临床应用中的研究进展[J]. 中华肾脏病杂志, 2024, 40(8): 680-684.doi:10.3760/cma.j.cn441217-20231011-01014.
[20]	Li Q, Chen R, An H, et al. A review of the pathogenesis of IgA vasculitis nephritis in children[J]. Iran J Pediatr, 2025, 35(1): e150310.doi:10.5812/ijp-150310.
[21]	Zhang C, Peng J, Liu Z, et al. Kidney involvement in autoinflammatory diseases[J]. Kidney Dis (Basel), 2023, 9(3): 157-172.doi:10.1159/000529917.
[22]	Xu C, Cui W, Zeng C, et al. Role of red cell distribution width, tumor necrosis factor-alpha, and interleukin-6 in immunoglobulin a vasculitis nephritis among Tibetan children in high-altitude areas[J]. BMC pediatrics, 2025, 25(1): 941.doi: 10.1186/s12887-025-06290-4.
[23]	Yuan L, Wang Q, Zhang S, et al. Correlation between serum inflammatory factors TNF-α, IL-8, IL-10 and Henoch-Schonlein purpura with renal function impairment[J]. Exp Ther Med, 2018, 15(4): 3924-3928.doi:10.3892/ETM.2018.5876. pmid: 29556266
[24]	Kim J, Song SH, Oh TR, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with chronic kidney disease[J]. Korean J Intern Med, 2023, 38(5): 725-733.doi:10.3904/kjim.2023.171.
[25]	Liu Y, Yu H, Luo Y, et al. The neutrophil-to-monocyte ratio: A superior inflammatory marker predicting poor prognosis in IgA nephropathy[J]. BMC Nephrol, 2025, 26(1): 567.doi:10.1186/s12882-025-04475-8.
[26]	Xi L, Xu S, Jiang Y, et al. Predictive value of laboratory indexes on renal involvement in children with Henoch-Schönlein purpura[J]. Int J Gen Med, 2021: 7951-7959.doi:10.2147/IJGM.S337437.
[27]	Li Q, Shi S, Liu L, et al. Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator for poor renal prognosis in adult IgA vasculitis with nephritis[J]. Int Immunopharmacol, 2022, 111: 109178.doi:10.1016/j.intimp.2022.109178.
[28]	余雅, 杨定平, 杨红霞, 等. 中性粒细胞与淋巴细胞比值对不同比例新月体紫癜性肾炎相关性分析[J]. 临床肾脏病杂志, 2020, 20(4): 287-292.doi:10.3969/j.issn.1671-2390.2020.04.005.
[29]	裘艺莎, 吴锴, 胡剑, 等. 全身免疫炎症指数在儿童紫癜性肾炎中的预测价值[J]. 安徽医药, 2024, 28(12): 2497-2501.doi:10.3969/j.issn.1009-6469.2024.12.033.
[30]	Wang Z, Wang X, Zou H, et al. The basic characteristics of the pentraxin family and their functions in tumor progression[J]. Front Immunol, 2020, 11: 1757.doi: 10.3389/fimmu.2020.01757. pmid: 33013829
[31]	Ge W, Wang HL, Sun RP. Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children[J]. Eur J Pediatr, 2014, 173(2): 213-218.doi:10.1007/s00431-013-2150-0. pmid: 23963627
[32]	Nurmi MS, Pérez-Alós L, Garred P, et al. Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity[J]. Clin Kidney J, 2024, 18(1):sfae395. doi:10.1093/ckj/sfae395.
[33]	Gu R, Zhi Y, Wang A, et al. The association between fractalkine/CX3CR1 axis with IgA vasculitis and nephritis[J]. Pediatr Res, 2026, 99(2):740-747. doi: 10.1038/s41390-025-03957-7.
[34]	Song Z, Nie Y, Yang L, et al. Predicting severe renal and gastrointestinal involvement in childhood immunoglobulin A vasculitis with routine laboratory parameters[J]. Dermatology, 2022, 238(4): 745-752.doi:10.1159/000519665.
[35]	Wu D, Lei L, Zhang H, et al. Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schönlein purpura nephropathy[J]. Pediatr Nephrol, 2023, 38(2): 431-438.doi:10.1007/s00467-022-05585-3.
[36]	Dumont C, Mérouani A, Ducruet T, et al. Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schönlein purpura[J]. Pediatr Nephrol, 2020, 35(5): 843-850.doi:10.1007/s00467-019-04445-x. pmid: 31932958
[37]	Yu G, Zhao J, Wang M, et al. Urinary C4d and progression of kidney disease in IgA vasculitis[J]. Nephrol Dial Transplant, 2024, 39(10): 1642-1648.doi:10.1093/ndt/gfae045.
[38]	Wright RD, Marro J, Northey S J, et al. Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Schönlein purpura) nephritis[J]. Pediatr Nephrol, 2023, 38(5): 1491-1498.doi:10.1007/s00467-022-05747-3.
[39]	Oikonomopoulou K, Ricklin D, Ward PA, et al. Interactions between coagulation and complement--their role in inflammation[J]. Semin Immunopathol, 2012, 34(1): 151-165.doi:10.1007/s00281-011-0280-x. pmid: 21811895
[40]	朱琨, 季伟, 田凌峰, 等. D-二聚体和血小板计数预测过敏性紫癜性肾炎的价值[J]. 江苏医药, 2024, 50(4): 372-375.doi:10.19460/j.cnki.0253-3685.2024.04.013.
[41]	Elmas AT, Tabel Y. Platelet counts in children with Henoch-Schonlein purpura-relationship to renal involvement[J]. J Clin Lab Anal, 2016, 30(1): 71-74.doi:10.1002/jcla.21817.
[42]	Nie YI, Song ZX, Tao J, et al. Correlations of serological markers with development of systemic involvement in adult immunoglobulin a vasculitis: A retrospective study of 259 patients in Central China[J]. Curr Med Sci, 2021, 41(5): 888-893.doi:10.1007/s11596-021-2440-0.
[43]	Xu H, Li W, Mao JH, et al. Association between red blood cell distribution width and Henoch-Schonlein purpura nephritis[J]. Medicine (Baltimore), 2017, 96(23): e7091.doi:10.1097/MD.0000000000007091.
[44]	Wang F, Huang L, Tang H, et al. Significance of glomerular fibrinogen deposition in children with Henoch-Schönlein purpura nephritis[J]. Ital J Pediatr, 2018, 44(1): 97.doi:10.1186/s13052-018-0538-1. pmid: 30115075
[45]	Zhu ZQ, Zhang T, Chang S, et al. AZGP1 as a potential biomarker of IgA vasculitis with nephritis in a children-based urinary proteomics study by diaPASEF[J]. Mol Med Rep, 2023, 28(2): 157.doi:10.3892/mmr.2023.13044.
[46]	Tan J, Pei G, Xu Y, et al. Serum bilirubin is correlated with the progression of IgA vasculitis with nephritis[J]. Front Med (Lausanne), 2021, 8: 596151.doi:10.3389/fmed.2021.596151.
[47]	朱宛莹, 王凌超, 韦娜, 等. 血清胆红素水平变化在IgA血管炎儿童发生肾损伤中的预测价值[J]. 医学研究杂志, 2025, 54(5): 88-92.doi:10.11969/j.issn.1673-548X.2025.05.017.
[48]	Yu P, Zhang P, Gao CL, et al. Clinicopathological significance and prognostic value of serum 25-hydroxyvitamin D₃ level in children with IgA vasculitis nephritis[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2025, 27(1): 55-61.doi:10.7499/j.issn.1008-8830.2408058.
[49]	Guo L, Zhu A, Li W, et al. Clinical prediction model for progression from henoch-schönlein purpura to nephritis in pediatric patients[J]. Am J Transl Res, 2024, 16(12): 7385-7395.doi:10.62347/xdor8531. pmid: 39822551
[50]	Audemard-Verger A, Pillebout E, Baldolli A, et al. Impact of aging on phenotype and prognosis in IgA vasculitis[J]. Rheumatology(Oxford), 2021, 60(9): 4245-4251.doi:10.1093/rheumatology/keaa921.
[51]	Chatpaitoon B, Rianthavorn P, Chanakul A, et al. Clinical characteristics and risk factors for kidney involvement in children with immunoglobulin A vasculitis[J]. Pediatr Int, 2024, 66(1): e15781.doi:10.1111/ped.15781.
[52]	Levanon S, Gotloib V, Kraus Y, et al. IgA vasculitis in adults, pediatrics and non-vasculitic IgA nephropathy, retrospective analysis from 2 centers[J]. Medicine (Baltimore), 2023, 102(50): e36521.doi:10.1097/md.0000000000036521.
[53]	Harvey BJ, Alvarez de la Rosa D. Sex differences in kidney health and disease[J]. Nephron, 2025, 149(2): 77-103.doi:10.1159/000541352.
[54]	Dunn SE, Perry WA, Klein SL. Mechanisms and consequences of sex differences in immune responses[J]. Nat Rev Nephrol, 2024, 20(1): 37-55.doi:10.1038/s41581-023-00787-w.
[55]	Kang Z, Xun M, Li Z, et al. Association of the clinicopathological characteristics and proteinuria remission of pediatric IgAV with nephrotic-range proteinuria: A retrospective cohort study[J]. Front Pediatr, 2022, 10: 959212.doi:10.3389/fped.2022.959212.
[56]	Liu Y, Wen M, He Q, et al. Lipid metabolism contribute to the pathogenesis of IgA vasculitis[J]. Diagn Pathol, 2022, 17(1): 28.doi:10.1186/s13000-021-01185-1. pmid: 35148801
[57]	Zheng X, Chen Q, Chen L. Obesity is associated with Henoch-Schönlein purpura nephritis and development of end-stage renal disease in children[J]. Ren Fail, 2019, 41(1): 1016-1120.doi:10.1080/0886022X.2019.1685545. pmid: 31735105
[58]	Gan MY, Chua FZY, Chang ZY, et al. Navigating adult-onset IgA vasculitis-associated nephritis[J]. Life (Basel), 2024, 14(8): 930.doi:10.3390/life14080930.
[59]	Held M, Stingl Jankovic K, Sestan M, et al. HLA polymorphisms and clinical manifestations in IgA vasculitis[J]. Int J Mol Sci, 2024, 25(2): 882.doi:10.3390/ijms25020882.
[60]	López-Mejías R, Carmona FD, Castañeda S, et al. A genome-wide association study suggests the HLA class II region as the major susceptibility locus for IgA vasculitis[J]. Sci Rep, 2017, 7(1): 5088.doi:10.1038/s41598-017-03915-2. pmid: 28698626
[61]	Xia L, Chen M, Zhang H, et al. Genome-wide association study of 7661 Chinese Han individuals and fine-mapping major histocompatibility complex identifies HLA-DRB1 as associated with IgA vasculitis[J]. J Clin Lab Anal, 2022, 36(6): e24457.doi:10.1002/jcla.24457.
[62]	Robson KJ, Ooi JD, Holdsworth SR, et al. HLA and kidney disease: From associations to mechanisms[J]. Nat Rev Nephrol, 2018, 14(10): 636-655.doi:10.1038/s41581-018-0057-8. pmid: 30206339
[63]	Jelusic M, Sestan M, Giani T, et al. New insights and challenges associated with IgA vasculitis and IgA vasculitis with nephritis-Is it time to change the paradigm of the most common systemic vasculitis in childhood?[J]. Front Pediatr, 2022, 10: 853724.doi:10.3389/fped.2022.853724.
[64]	Yu HH, Liu PH, Yang YH, et al. Chemokine MCP1/CCL2 and RANTES/CCL5 gene polymorphisms influence Henoch-Schönlein purpura susceptibility and severity[J]. J Formos Med Assoc, 2015, 114(4): 347-52.doi:10.1016/j.jfma.2012.12.007.
[65]	Sestan M, Jelusic M. Diagnostic and management strategies of IgA vasculitis nephritis/Henoch-Schönlein purpura nephritis in pediatric patients: Current perspectives[J]. Pediatric Health Med Ther, 2023: 89-98.doi:10.2147/PHMT.S379862.
[66]	Sestan M, Srsen S, Kifer N, et al. Persistence and severity of cutaneous manifestations in IgA vasculitis is associated with development of IgA vasculitis nephritis in children[J]. Dermatology, 2022, 238(2): 340-346.doi:10.1159/000516765.
[67]	Shimamura Y, Maeda T, Nishizawa K, et al. Gastrointestinal bleeding is associated with renal prognosis in adult patients with IgA vasculitis with nephritis[J]. J Gen Fam Med, 2020, 21(1): 10-17.doi:10.1002/jgf2.285. pmid: 31911884

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 67

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Zexian, Liu Yuxin, Shen Shipeng, Zhao Song, Gao Yiping, Liu Maodong. Chronic myeloid leukemia complicated by membranoproliferative glomerulonephritis: A case report and literature review [J]. Clinical Focus, 2026, 41(3): 259-263.
[2]	Song Chenlu, Qi Xiaojing, Chen Yipeng, Xing Guangqun. Association of poor living habits and smoking with primary membranous nephropathy [J]. Clinical Focus, 2025, 40(6): 513-518.
[3]	Zhao Hui, Zhang Pengwei, Zhang Jian, Huang Wenhui, Li Xiaoli, Ma Zhigang, Jin Fang, Tian Limin. IgA-dominant infection-related glomerulonephritis with oxalate deposition: A case report and literature review [J]. Clinical Focus, 2025, 40(2): 162-167.
[4]	Sun Shuaigang, Zhai Yaling, Zhang Wenhui, Tian Huijuan. Tonsillectomy as a therapy for patients with IgA nephropathy: A meta-analysis [J]. Clinical Focus, 2024, 39(3): 197-207.
[5]	Wang Tao, Gao Yuwei, Wang Xinghua, Hu Xiuhong, Cui Hongrui, Xu Baozhen, Yang Hongjuan. Correlation of anti-phospholipase A2 receptor antibody with idiopathic membranous nephropathy [J]. Clinical Focus, 2023, 38(7): 606-612.
[6]	Gao Qinyu, Bao Beiyan, Jin Yan, Zhao Yu. Analysis of clinical features and prognostic factors of IgA nephropathy complicated with depression [J]. Clinical Focus, 2023, 38(6): 510-515.
[7]	. [J]. Clinical Focus, 2022, 37(11): 1053-1056.
[8]	Gao Pengli, Chen Lili, Tian Fen, Zhang Jiaqian, Chen Yipeng, Qi Xiaojing, Xing Guangqun. Impact of body mass index in the clinicopathology and prognosis of patients with IgA nephropathy [J]. Clinical Focus, 2022, 37(3): 234-242.
[9]	. [J]. Clinical Focus, 2021, 36(6): 569-573.
[10]	Liu Jiali, Xie Rong, Li Xuelian, Liu Xiaohui. Correlation analysis between neutrophil/lymphocyte ratio with Lee’s grading and Oxford classification of IgA nephropathy [J]. Clinical Focus, 2021, 36(5): 432-435.
[11]	. [J]. CLINICAL FOCUS, 2013, 28(9): 1075-1078.
[12]	. [J]. CLINICAL FOCUS, 2013, 28(3): 342-347.
[13]	. [J]. Clinical Focus, 2012, 27(17): 1540-1542.
[14]	. [J]. Clinical Focus, 2012, 27(9): 795-797.
[15]	GE Xiao;WANG Yan-li;YANG Li-ya;CHEN Jun-feng;LIU Bi-chen. Cyclosporine A treatment for idiopathic membranous nephropathy: a systematic review and Meta-analysis [J]. Clinical Focus, 2012, 27(3): 196-201.